Budget Express 2026

co-presented by

ASSOCIATE SPONSORS

you are here: HomeNewsBusinessEarningsDishman Pharma expects 25% growth in FY13

SHOW NAMES

Trending Topics

business

Dishman Pharma expects 25% growth in FY13

Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.

first published: May 15, 2012 04:33 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347